• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection.

作者信息

Giannitti Chiara, Fineschi Irene, Frediani Bruno, Fioravanti Antonella, Galeazzi Mauro

机构信息

Rheumatology Unit, Department of Clinical Medicine and Immunological Science, University of Siena, Italy.

出版信息

Clin Exp Rheumatol. 2013 Sep-Oct;31(5):816. Epub 2013 Sep 9.

PMID:24021246
Abstract
摘要

相似文献

1
Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection.托珠单抗联合环孢素A治疗类风湿关节炎合并慢性丙型肝炎病毒感染患者的疗效与安全性
Clin Exp Rheumatol. 2013 Sep-Oct;31(5):816. Epub 2013 Sep 9.
2
Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection.抗TNF-α疗法联合环孢素A治疗类风湿关节炎合并丙型肝炎病毒感染患者的疗效和安全性。
Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):543-6. doi: 10.1177/039463200902200233.
3
Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection.
Rheumatology (Oxford). 2012 Aug;51(8):1520-1. doi: 10.1093/rheumatology/kes051. Epub 2012 Mar 30.
4
Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection.环孢素A与抗TNF-α药物联合治疗类风湿关节炎及合并丙型肝炎病毒感染
Clin Rheumatol. 2007 Jul;26(7):1127-9. doi: 10.1007/s10067-006-0412-1. Epub 2006 Dec 2.
5
Sarilumab (Kevzara) for rheumatoid arthritis.用于治疗类风湿性关节炎的药物——萨立鲁单抗（凯夫扎拉）
Med Lett Drugs Ther. 2017 Aug 14;59(1527):134-136.
6
[The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].托珠单抗联合改善病情抗风湿药治疗活动期类风湿关节炎的疗效和安全性：一项多中心、随机、双盲、安慰剂对照试验
Zhonghua Nei Ke Za Zhi. 2013 Apr;52(4):323-9.
7
[Immunosuppression may mask severe infection. Septic arthritis in tocilizumab treatment yielded only modest acute-phase reaction].免疫抑制可能掩盖严重感染。托珠单抗治疗中的化脓性关节炎仅产生适度的急性期反应。
Lakartidningen. 2012;109(38):1678-9.
8
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.托珠单抗治疗甲氨蝶呤应答不佳的中重度活动性类风湿关节炎患者的疗效：ROSE 研究。
Ann Rheum Dis. 2012 Feb;71(2):198-205. doi: 10.1136/ard.2010.148700. Epub 2011 Sep 26.
9
A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B.一名类风湿关节炎患者，在接受英夫利昔单抗治疗后乙型肝炎再激活缓解后，联合托珠单抗和拉米夫定预防治疗。
Mod Rheumatol. 2011 Dec;21(6):701-5. doi: 10.1007/s10165-011-0470-3. Epub 2011 May 29.
10
Treatment strategies for a patient with rheumatoid arthritis and hepatitis C.
Expert Opin Pharmacother. 2009 Mar;10(4):579-87. doi: 10.1517/14656560902731951.

引用本文的文献

1
Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.在乙肝病毒携带者状态的类风湿关节炎患者中，停用抗病毒预防措施与乙肝病毒（HBV）再激活的高发生率相关：一项真实世界临床实践。
BMC Musculoskelet Disord. 2014 Dec 22;15:449. doi: 10.1186/1471-2474-15-449.
2
Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis--synergy study: a longitudinal observational study.银屑病关节炎患者既往和再激活病毒感染的患病率以及环孢素A单药治疗或联合治疗的疗效——协同研究：一项纵向观察性研究
Biomed Res Int. 2014;2014:941767. doi: 10.1155/2014/941767. Epub 2014 Apr 3.